Review
Pharmacology & Pharmacy
Pooja Jain, Himanshu Kathuria, Munira Momin
Summary: Bladder cancer is the 10th most common malignancy worldwide with a 5-year survival rate of 75%, but 70% of the cases develop chemoresistance and progress to the muscle invasive stage. Nanotechnology has shown promise in targeted drug delivery to bladder cancer cells, offering potential for better treatment management.
PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Chemistry, Analytical
Heena Tyagi, Emma Daulton, Ayman S. Bannaga, Ramesh P. Arasaradnam, James A. Covington
Summary: Bladder cancer and prostate cancer are commonly diagnosed with invasive techniques, but a non-invasive diagnostic approach using volatile organic compounds (VOCs) shows promise. Analysis of urinary VOC profiles using GC-IMS and GC-TOF-MS can effectively distinguish between BCa and PCa, offering potential for cancer diagnosis.
Review
Medicine, Research & Experimental
Dimitrios Goutas, Andrianos Tzortzis, Harikleia Gakiopoulou, Dimitrios Vlachodimitropoulos, Ioanna Giannopoulou, Andreas C. Lazaris
Summary: Bladder cancer can be classified into basal and luminal molecular subtypes, with basal tumors responding better to immune checkpoint inhibitors but having worse prognosis, while luminal tumors respond better to FGFR3 and HER2. Tumors with squamous differentiation show better response to EGFR-targeting agents.
Article
Biochemistry & Molecular Biology
Sabina Galiniak, Mateusz Molon, Marek Biesiadecki, Agnieszka Mokrzynska, Krzysztof Balawender
Summary: Oxidative stress refers to an imbalance between the production of reactive oxygen species and antioxidant capacity, causing oxidative damage to biomolecules, cell injury, and eventually death. Our study aimed to determine markers of oxidative stress in serum and urine, and to investigate the relationship between these markers and bladder cancer. We found that almost all markers were elevated in the serum and urine of bladder cancer patients compared to healthy subjects. Additionally, we observed correlations between serum and urinary biomarkers, particularly TOS and OSI. Our results clearly indicate the involvement of oxidative stress in the development of bladder cancer.
Review
Biochemistry & Molecular Biology
Lucia Morales, Jesus M. Paramio
Summary: Bladder cancer presents a challenging problem in Oncology due to its high incidence and progression, leading to exploration of new avenues in its management. While immune checkpoint blockade inhibitors represent an unprecedented advance, the fraction of patients benefiting from them is limited. Cell-based therapies are promising tools for controlling solid tumors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Urology & Nephrology
Weranja Ranasinghe, Daniel D. Shapiro, Hyunsoo Hwang, Xuemei Wang, Chad A. Reichard, Mohamed Elsheshtawi, Mary F. Achim, Tharakeswara Bathala, Chad Tang, Ana Aparicio, Shi-Ming Tu, Nora Navone, Timothy C. Thompson, Louis Pisters, Patricia Troncoso, John W. Davis, Brian F. Chapin
Summary: This study demonstrates that patients with ductal adenocarcinoma of the prostate have worse outcomes compared to high-grade prostate adenocarcinoma patients, regardless of the treatment modality. Upregulation of intrinsic resistance pathways in DAC makes ADT less effective, highlighting the need for further evaluation of the underlying biology with clinical trials.
Article
Chemistry, Multidisciplinary
Shao-Yung Chen, Tung-Shing Mamie Lih, Qing Kay Li, Hui Zhang
Summary: In this study, the researchers enriched glycopeptides from urine samples and evaluated their contribution to cancer specificity. They identified specific glycopeptides associated with prostate cancer by analyzing urine samples from different urogenital cancer types. These findings deepen our understanding of urinary glycoproteins in urogenital cancer.
Article
Oncology
Jaena Park, Rebecca L. Kamerer, Marina Marjanovic, Janet E. Sorrells, Sixian You, Ronit Barkalifa, Kimberly A. Selting, Stephen A. Boppart
Summary: In this study, noninvasive, multimodal, label-free nonlinear optical microscopy was used to evaluate the optical redox ratio of large extracellular vesicles (EVs) isolated from the urine of 11 dogs. The study found that the optical redox ratio of urinary EVs may potentially serve as a screening biomarker for bladder cancer.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Amanda Kornel, Matteo Nadile, Maria Ilektra Retsidou, Minas Sakellakis, Katerina Gioti, Apostolos Beloukas, Newman Siu Kwan Sze, Panagiota Klentrou, Evangelia Tsiani
Summary: Prostate cancer is a major global health issue, with a high number of cases and deaths. Plant-derived compounds, such as ursolic acid found in cranberries, have shown promise in inhibiting the growth of prostate and other urogenital cancers. Further research and clinical studies are needed to fully understand the potential of ursolic acid in cancer prevention and treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Genetics & Heredity
Luciana Mastrodomenico, Claudia Piombino, Beatrice Ricco, Elena Barbieri, Marta Venturelli, Federico Piacentini, Massimo Dominici, Laura Cortesi, Angela Toss
Summary: Hereditary cancer syndromes are inherited disorders caused by germline pathogenic variants that increase the risk of developing certain types of cancer. The personalized treatment of hereditary tumors that target germline pathogenic variants has shown promising results in clinical trials.
Review
Chemistry, Multidisciplinary
Monika Nehra, U. T. Uthappa, Virendra Kumar, Rajesh Kumar, Chandra Dixit, Neeraj Dilbaghi, Yogendra Kumar Mishra, Sandeep Kumar, Ajeet Kaushik
Summary: This review explores the limitations of current brain cancer treatment and the potential benefits of using nanobiotechnology, such as nanocarriers and nano-assisted therapies, to improve efficacy and minimize adverse effects. The focus is on personalized approaches based on unique genetic characteristics of patients and their disease profiles, highlighting the emerging opportunities in nanotechnology for advancing brain cancer treatment.
JOURNAL OF CONTROLLED RELEASE
(2021)
Review
Immunology
Daniel O'Brian, Megan Prunty, Alexander Hill, Jonathan Shoag
Summary: C-Reactive Protein (CRP) is associated with various outcomes in patients with genitourinary malignancies, including prostate cancer diagnosis, biochemical recurrence, disease progression, stage, and cancer-specific survival in bladder and kidney cancers. Despite numerous correlative studies, the relationship between CRP levels and genitourinary cancer pathogenesis remains unclear.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Urology & Nephrology
James Ross, Lidia Avvakoumova, Alaya Yassein, Magdalene Payne, Conrad Maciejewski, Ranjeeta Mallick, Rodney H. Breau, Humberto Vigil, Duane Hickling
Summary: The study aims to review patients with chronic urinary symptoms and remote urethral sling surgery to determine the prevalence and predictors of obstruction. The results show that 60% of patients met the definition for obstruction, and those with obstruction had poorer performance in detrusor pressure and maximum urinary flow rate.
JOURNAL OF UROLOGY
(2023)
Editorial Material
Biochemistry & Molecular Biology
Nazli Dizman, Luis Meza, Sumanta K. Pal
Summary: The multi-arm clinical trial discussed the results of testing a treatment strategy for bladder cancer that combines standard immunotherapy with biomarker assessment and targeted therapies to improve efficacy.
Article
Biochemistry & Molecular Biology
Sujin Lee, Ja Yoon Ku, Byeong Jin Kang, Kyung Hwan Kim, Hong Koo Ha, Suhkmann Kim
Summary: This study investigated the urinary metabolic differences in male patients with prostate cancer, bladder cancer, and renal cell carcinoma to find distinct metabolites and potential biomarkers among the three cancers. The results showed significant differences in metabolite levels, particularly 4-hydroxybenzoate, N-methylhydantoin, creatinine, glutamine, and acetate. Receiver operating characteristic analysis demonstrated good discriminatory accuracy between the different types of cancers. This preliminary study highlights the potential of metabolomics in the exploration of human urine for cancer detection.
Letter
Urology & Nephrology
Alessia Cimadamore, Marina Scarpelli, Liang Cheng, Antonio Lopez-Beltran, Francesco Montorsi, Rodolfo Montironi
Review
Pathology
Alessia Cimadamore, Francesco Massari, Matteo Santoni, Veronica Mollica, Vincenzo Di Nunno, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, Rodolfo Montironi, Holger Moch
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
(2020)
Editorial Material
Pathology
Tania Franceschini, Francesca Giunchi, Rodolfo Montironi, Marina Scarpelli, Antonio Lopez-Beltran, Liang Cheng, Michelangelo Fiorentino
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
(2020)
Editorial Material
Pathology
Rodolfo Montironi, Liang Cheng, Alessia Cimadamore, Antonio Lopez-Beltran
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
(2020)
Editorial Material
Oncology
Alessia Cimadamore, Antonio Lopez-Beltran, Francesco Massari, Matteo Santoni, Roberta Mazzucchelli, Marina Scarpelli, Andrea B. Galosi, Liang Cheng, Rodolfo Montironi
Article
Oncology
Matteo Santoni, Daniel Y. Heng, Sergio Bracarda, Giuseppe Procopio, Michele Milella, Camillo Porta, Marc R. Matrana, Giacomo Carteni, Simon J. Crabb, Ugo De Giorgi, Umberto Basso, Cristina Masini, Fabio Calabro, Maria Giuseppa Vitale, Daniele Santini, Francesco Massari, Luca Galli, Giuseppe Fornarini, Riccardo Ricotta, Sebastiano Buti, Paolo Zucali, Orazio Caffo, Franco Morelli, Francesco Carrozza, Angelo Martignetti, Alain Gelibter, Roberto Iacovelli, Alessandra Mosca, Francesco Atzori, Nuno Vau, Lorena Incorvaia, Cinzia Ortega, Marina Scarpelli, Antonio Lopez-Beltran, Liang Cheng, Vittorio Paolucci, Jeffrey Graham, Erin Pierce, Sarah Scagliarini, Pierangela Sepe, Elena Verzoni, Sara Merler, Mimma Rizzo, Giulia Sorgentoni, Alessandro Conti, Francesco Piva, Alessia Cimadamore, Rodolfo Montironi, Nicola Battelli
Letter
Urology & Nephrology
Matteo Santoni, Francesco Massari, Giorgio Santoni, Alessia Cimadamore, Rodolfo Montironi, Nicola Battelli
Article
Oncology
Matteo Santoni, Francesco Massari, Enrique Grande, Giuseppe Procopio, Marc R. Matrana, Mimma Rizzo, Ugo De Giorgi, Umberto Basso, Michele Milella, Roberto Iacovelli, Gaetano Aurilio, Lorena Incorvaia, Sebastiano Buti, Orazio Caffo, Giuseppe Fornarini, Francesco Carrozza, Veronica Mollica, Alessandro Rizzo, Fady Farag, Javier Molina-Cerrillo, Nicola Battelli
Summary: The study analyzed the outcomes of patients with metastatic renal cell carcinoma with sarcomatoid features treated with cabozantinib, showing its efficacy in pretreated patients. Female sex, bone metastases, and International Metastatic Renal Cell Carcinoma Database Consortium criteria were significant predictors of worse overall survival.
Article
Oncology
Matteo Santoni, Gaetano Aurilio, Francesco Massari, Enrique Grande, Marc R. Matrana, Mimma Rizzo, Ugo De Giorgi, Lorena Incorvaia, Angelo Martignetti, Javier Molina-Cerrillo, Ignacio Ortego Zabalza, Veronica Mollica, Alessandro Rizzo, Nicola Battelli, Camillo Porta
Summary: This study compared the real-world efficacy of nivolumab and cabozantinib as second-line therapy for metastatic Renal Cell Carcinoma (mRCC) patients and found significant differences in overall survival and progression-free survival in specific subpopulations.
CLINICAL GENITOURINARY CANCER
(2022)
Article
Oncology
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Francesco Massari
Summary: This study analyzed the clinicopathological features of FGFR3-mutated UTUC patients using public datasets and found that FGFR3 mutations may serve as a prognostic factor, and are more frequent in low-grade UTUCs with early-stage disease.
CLINICAL GENITOURINARY CANCER
(2022)
Meeting Abstract
Oncology
A. Rizzo, V. Mollica, M. Santoni, F. Massari
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Matteo Santoni, Francesco Massari, Marc R. Matrana, Umberto Basso, Ugo De Giorgi, Gaetano Aurilio, Sebastiano Buti, Lorena Incorvaia, Mimma Rizzo, Angelo Martignetti, Diana Maslov, Karine Tawagi, Ernest Philon, Zoe Blake, Camillo Porta, Nicola Battelli
Summary: This study suggests a prognostic impact of statin use in patients receiving nivolumab for metastatic renal cell carcinoma (mRCC), with longer overall survival (OS) and progression-free survival (PFS) observed in statin users, especially among patients aged 70 and above.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Matteo Santoni, Francesco Massari, Zin W. Myint, Roberto Iacovelli, Martin Pichler, Umberto Basso, Jindrich Kopecky, Jakub Kucharz, Sebastiano Buti, Alessia Salfi, Thomas Buettner, Ugo De Giorgi, Ravindran Kanesvaran, Ondrej Fiala, Enrique Grande, Paolo Andrea Zucali, Giuseppe Fornarini, Maria T. Bourlon, Sarah Scagliarini, Javier Molina-Cerrillo, Gaetano Aurilio, Marc R. Matrana, Renate Pichler, Carlo Cattrini, Tomas Buechler, Emmanuel Seront, Fabio Calabro, Alvaro Pinto, Rossana Berardi, Anca Zgura, Giulia Mammone, Jawaher Ansari, Francesco Atzori, Rita Chiari, Roubini Zakopoulou, Orazio Caffo, Giuseppe Procopio, Maria Bassanelli, Ilaria Zampiva, Carlo Messina, Zsofia Kueronya, Alessandra Mosca, Dipen Bhuva, Nuno Vau, Lorena Incorvaia, Sara Elena Rebuzzi, Giandomenico Roviello, Ignacio Ortego Zabalza, Alessandro Rizzo, Veronica Mollica, Ilaria Catalini, Fernando Sabino M. Monteiro, Rodolfo Montironi, Nicola Battelli, Mimma Rizzo, Camillo Porta
Summary: Obesity is associated with improved response to immunotherapy in metastatic renal cell carcinoma, but its prognostic significance and association vary across subgroups.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Oncology
Matteo Santoni, Francesco Massari, Zin W. Myint, Roberto Iacovelli, Martin Pichler, Umberto Basso, Jindrich Kopecky, Jakub Kucharz, Sebastiano Buti, Mimma Rizzo, Luca Galli, Thomas Buettner, Ugo De Giorgi, Ravindran Kanesvaran, Ondrej Fiala, Enrique Grande, Paolo Andrea Zucali, Giuseppe Fornarini, Maria T. Bourlon, Sarah Scagliarini, Javier Molina-Cerrillo, Gaetano Aurilio, Marc R. Matrana, Renate Pichler, Carlo Cattrini, Tomas Buechler, Emmanuel Seront, Fabio Calabro, Alvaro Pinto, Rossana Berardi, Anca Zgura, Giulia Mammone, Jawaher Ansari, Francesco Atzori, Rita Chiari, Aristotelis Bamias, Orazio Caffo, Giuseppe Procopio, Maria Bassanelli, Sara Merler, Carlo Messina, Zsofia Kueronya, Alessandra Mosca, Dipen Bhuva, Nuno Vau, Lorena Incorvaia, Sara Elena Rebuzzi, Giandomenico Roviello, Ignacio Ortego Zabalza, Alessandro Rizzo, Veronica Mollica, Giulia Sorgentoni, Fernando Sabino M. Monteiro, Rodolfo Montironi, Nicola Battelli, Camillo Porta
Summary: The ARON-1 study collected real-world data on the use of immuno-combination therapies as first-line treatment for mRCC patients globally. The study showed that immuno-combination therapies are effective in the real-world context of mRCC, with longer survival observed in patients treated with IO + TKI combinations compared to IO + IO combinations in the intermediate/poor risk population.
Article
Pathology
Svitlana Y. Bachurska, Petar A. Antonov, Ivan Y. Dechev, Antonio Lopez-Beltran
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY
(2020)